SEC Form 4 · accession 0001864158-26-000004
Janux Therapeutics, Inc. · JANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Alan Campbell
Officer — President and CEO · Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817713
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2026 | M | 7,000 | $4.21 | A | 388,582 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.21 | Jul 8, 2026 | M | 7,000 | D | — | Mar 9, 2031 | Common Stock | 7,000 | 697,550 | D |
Explanation of responses
- F1Immediately exercisable.